ArticleCancer gene therapy2001
Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells.
Article in Cancer gene therapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 77 citations in OpenAlex.
- Applying CRISPR Technologies for the Treatment of Human Herpesvirus Infections: A Scoping Review.Pathogens (Basel, Switzerland) · 2025Article
- Single-Step Non-Chromatographic Purification of Recombinant Mammalian Proteins Using a Split Intein ELP Tag System.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Enzymatic ligation of an antibody and arginine 9 peptide for efficient and cell-specific siRNA delivery.Scientific reports · 2021Article
- Extracellular Vesicle-MediatedMolecular cancer therapeutics · 2020Article
- ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling.International journal of molecular sciences · 2018Article
- Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation.Molecular cancer therapeutics · 2018Article
- Decomposing Dynamical Couplings in Mutated scFv Antibody Fragments into Stabilizing and Destabilizing Effects.Journal of the American Chemical Society · 2017Article
- [Construction and verification of anti-MM scFv-tP fusion protein expression vector].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2017Article
- Lipopolyplex for Therapeutic Gene Delivery and Its Application for the Treatment of Parkinson's Disease.Frontiers in aging neuroscience · 2016Review
- Design and characterization of novel recombinant listeriolysin O-protamine fusion proteins for enhanced gene delivery.Molecular pharmaceutics · 2015Article
- Article
- Applying horizontal gene transfer phenomena to enhance non-viral gene therapy.Journal of controlled release : official journal of the Controlled Release Society · 2013Review
- Development of an MRI-visible nonviral vector for siRNA delivery targeting gastric cancer.International journal of nanomedicine · 2012Article
- scFv antibody: principles and clinical application.Clinical & developmental immunology · 2012Review
- Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides.Therapeutic delivery · 2011Review
- In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.Cancer biotherapy & radiopharmaceuticals · 2010Article
- Epidermal growth factor targeting of bacteriophage to the choroid plexus for gene delivery to the central nervous system via cerebrospinal fluid.Brain research · 2010Article
- The role of HER2 in cancer therapy and targeted drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2010Review
- Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2010Article
- Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma.Cancer research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted gene transfer by nonviral vectors can be achieved through incorporation of specific ligand(s) into the vectors. In this study, the effects of incorporation of an anti-ErbB2 single-chain antibody fragment (ScFv) into nonviral vectors for targeted gene delivery were investigated. The ML39 ScFv, selected from a human ScFv phage display library and affinity matured in vitro (K(d)=1 x 10(-9) M), was used as ligand specific for the extracellular domain of the tumor surface protein, ErbB2. Two approaches were taken: (a) development of a vector that is composed of a bifunctional fusion protein capable of binding DNA with the ErbB2-specific ML39 ScFv at its N-terminus and a truncated form of human protamine at its C-terminus, and (b) formulation and evaluation of delivery vectors consisting of three independent components including ML39 ScFv, protamine, and cationic lipids. We demonstrate that fusion proteins comprised of the ML39 ScFv and a truncated form of protamine, denoted as ScFv-P-S, can selectively deliver exogenous DNA into ErbB2(+) cells, with an 8- to 10-fold increase in expression levels of the luciferase reporter gene in ErbB2(+) cells as compared to ErbB2(-) cells. In addition, vectors formulated by appropriately mixing DNA, ScFv, protamine, and lipids in vitro could even more efficiently deliver the reporter gene into ErbB2(+) cells with approximately 5-fold increase in gene expression in ErbB2(+) cell as compared to ErbB2(-) cells. Expression and refolding of the ScFv fusion proteins, in addition to determination of optimal conditions for vector development using these approaches, are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.